Statins and Thyroidectomy May Reduce the Risk of Orbitopathy Developing in Patients with Graves’ Disease
نویسنده
چکیده
Background Graves’ orbitopathy (GO) is a component of Graves’ disease (GD) that is difficult to treat and may be very debilitating for the patient. Orbitopathy (ophthalmopathy [harder to pronounce]) is a significant problem for about 5% to 10% of patients with Graves’ disease. The factors that cause a predisposition to it are not clear. The current study examines a database of patients with Graves’ disease in order to determine what factors predispose to orbitopathy.
منابع مشابه
Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer
The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisit...
متن کاملIs Recombinant Human TSH a Trigger for Graves' Orbitopathy?
The pathogenesis of Graves' orbitopathy (GO) remains unknown. The hypothesis of a causal relationship between autoimmunity against the TSH receptor (TSHR) and GO is supported by clinical studies. Radioiodine treatment is associated with worsening or new onset of GO, possibly via antigen shedding or by inducing hypothyroidism. The coexistence of thyroid cancer with Graves' disease (GD) and GO is...
متن کاملManagement of thyroid ophthalmopathy: the approach and challenges
Thyroid ophthalmopathy, or Graves’ ophthalmopathy, is the most common cause of exophthalmos in adults. Graves first described thyroid disease with associated ophthalmopathy in 1835. To date, the pathogenesis of thyroid ophthalmopathy remains speculative, as reflected by the numerous names by which it is described such as dysthyroid ophthalmopathy or thyroid eye disease, thyroid orbitopathy, eut...
متن کاملCD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
Graves' disease, an autoimmune disease with heterogeneous symptoms including Graves' orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers.Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15...
متن کاملEffects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement
drug (ATD) treatment [5], or to occur or worsen after a period of uncontrolled hypothyroidism [6]. Accordingly, the European Group on Graves’ Orbitopathy (EUGOGO) Consensus Statement few years ago recommended that restoration and maintenance of euthyroidism are priorities in Graves’ disease patients with GO [7]. How to treat hyperthyroidism when GO is present is, however, a challenging dilemma ...
متن کامل